Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rory L Smoot

Showing results (141-150 of 152) with videos related to

Pageof 16
Sort By:
Frontiers in Oncology|May 28, 2021
Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9Roman O Kowalchuk, Scott C Lester, Rondell P Graham, et al.
Annals of Surgical Oncology|March 11, 2025
Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort StudyJennifer L Leiting, Roberto Alva-Ruiz, Jennifer A Yonkus, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 7, 2019
Safety, Diagnostic Accuracy, and Effects of Endoscopic Ultrasound Fine-Needle Aspiration on Detection of Extravascular Migratory MetastasesTarun Rustagi, Ferga C Gleeson, Suresh T Chari, et al.
Journal of Surgical Oncology|June 2, 2026
Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage FluidKrystal Mills, Calise K Berger, William R Taylor, et al.
Journal of Hepatology|September 26, 2022
LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinomaCaitlin B Conboy, Jennifer A Yonkus, EeeLN H Buckarma, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
Hepatology (Baltimore, Md.)|September 29, 2025
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic targetDong-Gi Mun, Erik Jessen, Jennifer L Tomlinson, et al.
Hepatology Communications|November 16, 2021
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and <sup>68</sup> Ga-PSMA-11 PET Using Cyclotron-Produced <sup>68</sup> GaScott M Thompson, Garima Suman, Michael S Torbenson, et al.
Annals of Surgery|October 20, 2023
An APRI+ALBI-Based Multivariable Model as a Preoperative Predictor for Posthepatectomy Liver FailureJonas Santol, Sarang Kim, Lindsey A Gregory, et al.
Cancer Discovery|June 15, 2021
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient ScreeningGadi Lalazar, David Requena, Lavoisier Ramos-Espiritu, et al.
Pageof 16

Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
Frontiers in Oncology|May 28, 2021
Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9Roman O Kowalchuk, Scott C Lester, Rondell P Graham, et al.
Annals of Surgical Oncology|March 11, 2025
Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort StudyJennifer L Leiting, Roberto Alva-Ruiz, Jennifer A Yonkus, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 7, 2019
Safety, Diagnostic Accuracy, and Effects of Endoscopic Ultrasound Fine-Needle Aspiration on Detection of Extravascular Migratory MetastasesTarun Rustagi, Ferga C Gleeson, Suresh T Chari, et al.
Journal of Surgical Oncology|June 2, 2026
Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage FluidKrystal Mills, Calise K Berger, William R Taylor, et al.
Journal of Hepatology|September 26, 2022
LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinomaCaitlin B Conboy, Jennifer A Yonkus, EeeLN H Buckarma, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
Hepatology (Baltimore, Md.)|September 29, 2025
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic targetDong-Gi Mun, Erik Jessen, Jennifer L Tomlinson, et al.
Hepatology Communications|November 16, 2021
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and <sup>68</sup> Ga-PSMA-11 PET Using Cyclotron-Produced <sup>68</sup> GaScott M Thompson, Garima Suman, Michael S Torbenson, et al.
Annals of Surgery|October 20, 2023
An APRI+ALBI-Based Multivariable Model as a Preoperative Predictor for Posthepatectomy Liver FailureJonas Santol, Sarang Kim, Lindsey A Gregory, et al.
Cancer Discovery|June 15, 2021
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient ScreeningGadi Lalazar, David Requena, Lavoisier Ramos-Espiritu, et al.
Pageof 16